Mouse and human liver study: zinc-dependent ZFP36L1, hepatocyte senescence and alcohol-related liver disease
In mice, deleting hepatocyte ZFP36L1 worsened experimental alcohol-related liver disease; in human liver explants, ZFP36L1 activity fell as hepatocyte senescence and disease severity rose. This is an abstract; the full text was not reviewed. [1]
Automatic summary · not editorially reviewed
The key findings
Selective deletion of ZFP36L1 in mouse hepatocytes worsened experimental alcohol-related liver disease. [1]
ZFP36L1 directly destabilised Cdkn1a (p21) and Jag1 messenger RNAs, suppressing hepatocyte senescence and JAG1-NOTCH signalling. [1]
In human liver explants, ZFP36L1 activity declined in parallel with increasing hepatocyte senescence and ALD severity and was associated with impaired zinc-dependent signalling. [1]
The source at a glance
- Study type / format
- Experimental mouse study with parallel analysis of human liver explants (abstract).
- Population / context
- Mouse hepatocytes with ZFP36L1 deleted and human liver explants.
- Summary based on
- Study abstract
- Original publication
- October 7, 2026
ZFP36L1 deletion in mouse hepatocytes and alcohol-related liver disease
The researchers selectively deleted ZFP36L1 in mouse hepatocytes to test its effect on alcohol-related liver disease (ALD). Deletion worsened experimental ALD and activated programmes driving ductal transdifferentiation, inflammation and senescence. Mechanistically, ZFP36L1 directly destabilised Cdkn1a (p21) and Jag1 messenger RNAs, thereby suppressing hepatocyte senescence and JAG1-NOTCH signalling. These are mouse experiments; they do not show that the same manipulation affects human disease course.
Supporting source [1]
Human liver explants: lower ZFP36L1 activity with more senescence
In parallel, the authors analysed human liver explants. There, ZFP36L1 activity declined in parallel with increasing hepatocyte senescence and ALD severity and was closely associated with impaired zinc-dependent signalling. These are associations in explanted tissue, not proof that ZFP36L1 causes more severe disease in people.
Supporting source [1]
Zinc manipulation changed ZFP36L1 activity in the experiments
Changing zinc availability altered ZFP36L1 activity and the expression of its direct targets. The abstract describes ZFP36L1 as a promising therapeutic target in ALD, but this is a proposal from early experimental work, not a validated treatment. The abstract does not report sample sizes, follow-up or how the human explants were selected.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract reports no sample sizes, follow-up or selection details for the human explants. Mouse and explant findings are not evidence of a validated human therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Dutta RK, Du K, Ren N, Umbaugh DS, Oh SH, Wang L, Kalsotra A, Blackshear PJ, Diehl AM. · europepmc.org · October 7, 2026